



## Liposomal Drug Delivery: Three Decades from the First Liposomal Drug Delivery Medicine in Clinical Use

Guest Editors:

### Dr. Natassa Pippa

Department of Pharmacy,  
National & Kapodistrian  
University of Athens, Athens,  
Greece

### Dr. Asterios (Stergios) Pispas

Theoretical and Physical  
Chemistry Institute, National  
Hellenic Research Foundation, 48  
Vassileos Constantinou Ave.,  
11635 Athens, Greece

Deadline for manuscript  
submissions:  
**closed (31 October 2023)**

### Message from the Guest Editors

Dear Colleagues,

Liposomes are the first nanomedicines approved three decades back. From then to today, liposomal drug delivery have consistently played a central role in nanomedicine. Liposomal drugs are marketed medicines with great potential in the field of cancer therapy as well as other chronic and infectious diseases.

This Special Issue is concerned with the applications of liposomes in physical chemistry, biology, pharmaceutical technology, and medicine. Topics may include physicochemical studies, self-assembly behavior, interactions of lipids/liposomes with active pharmaceutical ingredients and/or other excipients, the impact of liposomes on the drug release mechanism, as well as the utilization of liposomes as models of cellular membranes. The formation, preparation, and drug loading/release of lipid-based nanocarriers, liposomes, and hybrid liposomal carriers (combination with other nanomaterials) are hot topics in the current literature. Special attention will be given to applications of liposomes in the delivery of proteins/nucleic acids, in vaccinology, and immunology of cancer. Both original manuscripts and reviews are welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI